Investors and Media
Press Releases
August 7, 2026
Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date
August 6, 2026
Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights
July 29, 2026
Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference
July 20, 2026
Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)
July 17, 2026
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 16, 2026
Scholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026
June 22, 2026
Scholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD
June 12, 2026
